Fortrea inks deal with Australia’s Incannex for sleep apnea drug trial

27 Jul 2023
www.fiercebiotech.com
Phase 3Phase 2
Fortrea inks deal with Australia’s Incannex for sleep apnea drug trial
Preview
Source: FierceBiotech
Fresh off its spinoff from Labcorp, CRO Fortrea has signed a deal with Incannex Healthcare to manage clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.
Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug (IND) clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.
The phase 2 and phase 3 trials will be designed to assess Incannex’s IHL-42X, a low dose of the anti-nausea drug dronabinol, a synthetic form of tetrahydrocannabinol (THC), and the diuretic acetazolamide.
A fairly common condition, obstructive sleep apnea causes the walls of the throat to relax and narrow during sleep, interrupting normal breathing that can lead to regularly interrupted sleep. In more severe cases, the condition can temporarily stop breathing during sleep.
Fortrea—the CRO spinoff from Labcorp—was previously engaged in a 12-week operational feasibility study of the trial that was provided to potential investigators to gauge their interest, the company said in a July 18 press release. While 63 sites said they were interested, Incannex is targeting 45 for the study.
“Fortrea’s familiarity with the study and established relationships with potential trial sites will expedite the study start-up and site engagement activities,” Joel Latham, Incannex chief executive and managing director, said in the release.
Labcorp announced plans last July to spin off its CRO operations into an independent, publicly traded company dubbed Fortrea. While under the Labcorp umbrella, the division reaped $3 billion in revenue in 2022, accounting for between 15% to 20% of Labcorp’s central lab business.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.